Hiv Clinical Trial
— IMARA-SA pilotOfficial title:
Multilevel Comprehensive HIV Prevention Package for South African Adolescent Girls and Young Women
Verified date | August 2022 |
Source | University of Illinois at Chicago |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Programs which go beyond individual-level behavior change to reduce HIV and STI infections among adolescent girls and young women in sub-Saharan Africa are essential to meet global HIV targets. Informed, Motivated, Aware and Responsible Adolescents and Adults- South Africa (IMARA-SA) is an evidence-based HIV-prevention intervention for adolescent girls and young women (AGYW) and their female caregivers, which has been adapted for a South African audience. This pilot study will assess feasibility in preparation for a randomized controlled trial (RCT). Additionally, the pilot will examine the preliminary effectiveness of IMARA-SA in reducing sexually transmitted infections (STI) and increasing uptake of HIV testing and counseling (HTC) and pre-exposure prophylaxis (PrEP) at follow-up among AGYW. About 60 AGYW-FC dyads will be enrolled and randomized to IMARA-SA or a health-promotion control arm. Following randomization, the dyads will participate in an ~2-day group workshop (~10 hours), which includes joint and separate mother and daughter activities. AGYW and FC will complete baseline assessments and follow-up assessments approximately 6 months later. Assessments will include surveys, STIs testing (for chlamydia and gonorrhea), and uptake of HTC and a 1-month PrEP prescription. Additionally, the intervention's implementation (e.g., acceptability) will be explored.
Status | Completed |
Enrollment | 120 |
Est. completion date | May 15, 2021 |
Est. primary completion date | May 15, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 15 Years to 19 Years |
Eligibility | Inclusion criteria for AGYW include: 1. Black or mixed race; 2. 15-19 years-old; 3. residing in Klipfontein/Mitchells Plain (K/MP); 4. speak isiXhosa or English or a combination of these languages. Inclusion criteria for FC include: 1. identified by AGYW as a FC; 2. 24 years and older; 3. living with or in daily contact with the AGYW; 4. speak isiXhosa or English or a combination of these languages. Exclusion Criteria: AGYW will be excluded from the study if they do not have a FC to participate in the study. AGYW and FC will be excluded from the study if they: 1. are unable to understand the consent/assent process and provide written informed consent; 2. are currently enrolled in another research study addressing HIV/STIs/PrEP; 3. participated in the IMARA-SA adaptation process. AGYW and FC must agree to participate as a dyad. AGYW refusal will supersede FC consent. |
Country | Name | City | State |
---|---|---|---|
South Africa | Desmond Tutu HIV Centre | Cape Town | Western Cape |
Lead Sponsor | Collaborator |
---|---|
University of Illinois at Chicago | Desmond Tutu HIV Centre, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
South Africa,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Intervention reach | Reach will be assessed as the proportion of AGYW who consented/assented to participate in the study. | ~6 months (from baseline to follow-up) | |
Other | Intervention feasibility | Feasibility will be measured as the proportion of AGYW in the IMARA-SA group who attend at least one session and receive the full 10-hour intervention. | ~6 months (from baseline to follow-up) | |
Other | Intervention acceptability | Acceptability will be measured through survey items completed by AGYW in the IMARA-SA group (e.g., satisfaction with the intervention day, perceptions of their facilitators, etc.). | ~6 months (from baseline to follow-up) | |
Other | Intervention fidelity | Fidelity will be assessed by observers of the intervention using an adapted version of the Treatment Fidelity Questionnaire (Lane et al, 2004). | ~6 months (from baseline to follow-up) | |
Primary | Proportion of adolescent girls and young women (AGYW) with a sexually transmitted infection (STI) at baseline and follow-up | A positive test for at least one of two STIs: chlamydia and/or gonorrhea | ~6 months (from baseline to follow-up) | |
Primary | Proportion of AGYW who complete HIV testing and counseling (HTC) at baseline and follow-up | Completion of HTC | ~6 months (from baseline to follow-up) | |
Primary | Proportion of AGYW who elect to take pre-exposure prophylaxis (PrEP) at baseline and follow-up | Uptake of PrEP | ~6 months (from baseline to follow-up) | |
Secondary | Proportion of AGYW who report risky sexual behavior at baseline and follow-up | Sexual behavior (e.g., condom use, substance use during sex, number of partners, concurrent partners) will be measured via self-report using the AIDS Risk Behavior Assessment (ARBA) (Donenberg, 2001) | ~6 months (from baseline to follow-up) | |
Secondary | Proportion of AGYW who report adherence to PrEP at baseline and follow-up | Adherence to PrEP (where appropriate) will be measured via self-report using items from the Wilson scale (2017) | ~6 months (from baseline to follow-up) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |